<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03359395</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00045800</org_study_id>
    <nct_id>NCT03359395</nct_id>
  </id_info>
  <brief_title>Pre-medication With Alfentanil vs Placebo During ECT</brief_title>
  <official_title>Effects of Pre-medication With Alfentanil on Hemodynamics During and Immediately Following Electroconvulsive Therapy (ECT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hemodynamic changes associated with the conduct of electroconvulsive therapy may be minimized&#xD;
      with the administration of alfentanil as part of their anesthetic regimen. This study&#xD;
      proposes to compare the effects in a blinded fashion. Currently alfentanil is an FDA approved&#xD;
      drug used on a daily basis by anesthesiologists on other surgeries so this is not a new&#xD;
      indication.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Electroconvulsive therapy is associated with brief hemodynamic alterations that in some&#xD;
      patients may be well outside the range of normalcy and potentially dangerous to the patient&#xD;
      (Duma A, et al). This cardiovascular response is caused by activation of the autonomic&#xD;
      nervous system and consists of an initial parasympathetic response rapidly followed by&#xD;
      sympathetically mediated tachycardia and hypertension. The ultra-short acting synthetic&#xD;
      opioid alfentanil has a rapid onset and duration of action that mirrors the duration of&#xD;
      hemodynamic perturbation associated with Electroconvulsive Therapy (ECT) while having minimal&#xD;
      or no effect on the duration or quality of the seizure. This drug may be effective in&#xD;
      blunting the hemodynamic perturbations associated with ECT with a minimal amount of side&#xD;
      effects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 4, 2018</start_date>
  <completion_date type="Actual">February 17, 2020</completion_date>
  <primary_completion_date type="Actual">February 17, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>study med prepared by a provider not involved in the anesthesia care of the subject</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Systolic Blood Pressure Change</measure>
    <time_frame>Baseline and up to 90 minutes</time_frame>
    <description>comparison of Systolic blood pressure changes alfentanil vs placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diastolic Blood Pressure Change</measure>
    <time_frame>Baseline and up to 90 minutes</time_frame>
    <description>comparison of diastolic blood pressure change alfentanil vs placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate</measure>
    <time_frame>Baseline and up to 15 seconds</time_frame>
    <description>comparison of heart rate change alfentanil vs placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate</measure>
    <time_frame>Baseline and up to 30 seconds</time_frame>
    <description>comparison of heart rate change alfentanil vs placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate</measure>
    <time_frame>90 minutes</time_frame>
    <description>comparison of heart rate change alfentanil vs placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Heart Rate</measure>
    <time_frame>Baseline and up to 90 minutes</time_frame>
    <description>comparison of heart rate change alfentanil vs placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum Heart Rate</measure>
    <time_frame>Baseline and up to 90 minutes</time_frame>
    <description>comparison of heart rate change alfentanil vs placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Doses of Antihypertensive Medication</measure>
    <time_frame>90 minutes</time_frame>
    <description>comparison of amounts of medications needed to treat blood pressure between the 2 groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Return of Spontaneous Ventilation</measure>
    <time_frame>up to 90 minutes</time_frame>
    <description>time to return to breathing without assistance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Time Subject Spent In-Room</measure>
    <time_frame>up to 90 minutes</time_frame>
    <description>comparison of amounts time spent in-room between the 2 groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of Headache in the Post Anesthesia Care Unit</measure>
    <time_frame>up to 90 minutes</time_frame>
    <description>comparison between alfentanil vs placebo - Subject questionnaire with scale: 0 -10 - with 10 being the worst</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction With the Anesthetic Post-procedure</measure>
    <time_frame>up to 90 minutes</time_frame>
    <description>comparison between alfentanil vs placebo - Subject questionnaire with scale: 0-10 - with 10 being the worst</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Blood Pressure</condition>
  <condition>Electroconvulsive Therapy</condition>
  <arm_group>
    <arm_group_label>Alfentanil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alfentanil</intervention_name>
    <description>Administration of alfentanil during the induction and maintenance of anesthesia for electroconvulsive therapy to be performed</description>
    <arm_group_label>Alfentanil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Administration of a equidose placebo during the induction and maintenance of anesthesia for electroconvulsive therapy to be performed</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; /=18 years&#xD;
&#xD;
          -  Males or females&#xD;
&#xD;
          -  Anticipating electroconvulsive therapy to treat refractory depressive disorder&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Under the age of 18&#xD;
&#xD;
          -  Allergy to alfentanil&#xD;
&#xD;
          -  Allergy to other standard anesthetic medications utilized in the course of ECT&#xD;
             (glycopyrrolate, methohexital, and succinylcholine)&#xD;
&#xD;
          -  History of malignant hyperthermia&#xD;
&#xD;
          -  History of severe airway obstruction, bronchospasm or laryngospasm&#xD;
&#xD;
          -  History of recent myocardial infarction, ventricular arrhythmia&#xD;
&#xD;
          -  Adverse reaction to ECT requiring premedication with lidocaine or atropine&#xD;
&#xD;
          -  Non-English speaking&#xD;
&#xD;
          -  Patients unable to consent for themselves&#xD;
&#xD;
          -  Current pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Quinn McCutchen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest School of Medicne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wake Forest University School of Medicine</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>November 27, 2017</study_first_submitted>
  <study_first_submitted_qc>November 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2017</study_first_posted>
  <results_first_submitted>April 28, 2021</results_first_submitted>
  <results_first_submitted_qc>July 7, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 8, 2021</results_first_posted>
  <last_update_submitted>July 7, 2021</last_update_submitted>
  <last_update_submitted_qc>July 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anesthesia</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alfentanil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 27, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/95/NCT03359395/Prot_SAP_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 2, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/95/NCT03359395/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>One Subject Withdrew before randomization</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Alfentanil Then Placebo</title>
          <description>Alfentanil: Administration of alfentanil during the induction and maintenance of anesthesia for electroconvulsive therapy to be performed</description>
        </group>
        <group group_id="P2">
          <title>Placebo Then Afentanil</title>
          <description>Placebos: Administration of a equidose placebo during the induction and maintenance of anesthesia for electroconvulsive therapy to be performed</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention A / B</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Intervention B/A</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Exclusion criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Alfentanil Then Placebo Arm 1</title>
          <description>Alfentanil: Administration of alfentanil during the induction and maintenance of anesthesia for electroconvulsive therapy to be performed</description>
        </group>
        <group group_id="B2">
          <title>Placebo Then Alfentanil Arm 2</title>
          <description>Placebos: Administration of a equidose placebo during the induction and maintenance of anesthesia for electroconvulsive therapy to be performed</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="49"/>
            <count group_id="B2" value="50"/>
            <count group_id="B3" value="99"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.34" spread="17.10"/>
                    <measurement group_id="B2" value="51.94" spread="13.96"/>
                    <measurement group_id="B3" value="51.621" spread="15.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="67"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="96"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="94"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height (cm)</title>
          <units>Centimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="167.57" spread="11.31"/>
                    <measurement group_id="B2" value="167.59" spread="10.25"/>
                    <measurement group_id="B3" value="167.58" spread="10.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight (kg)</title>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="86.28" spread="31.57"/>
                    <measurement group_id="B2" value="85.156" spread="27.33"/>
                    <measurement group_id="B3" value="85.405" spread="30.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Systolic Blood Pressure Change</title>
        <description>comparison of Systolic blood pressure changes alfentanil vs placebo</description>
        <time_frame>Baseline and up to 90 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Alfentanil</title>
            <description>Alfentanil: Administration of alfentanil during the induction and maintenance of anesthesia for electroconvulsive therapy to be performed</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebos: Administration of a equidose placebo during the induction and maintenance of anesthesia for electroconvulsive therapy to be performed</description>
          </group>
        </group_list>
        <measure>
          <title>Systolic Blood Pressure Change</title>
          <description>comparison of Systolic blood pressure changes alfentanil vs placebo</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.011" spread="36.968"/>
                    <measurement group_id="O2" value="38.908" spread="33.50864"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Diastolic Blood Pressure Change</title>
        <description>comparison of diastolic blood pressure change alfentanil vs placebo</description>
        <time_frame>Baseline and up to 90 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Alfentanil</title>
            <description>Alfentanil: Administration of alfentanil during the induction and maintenance of anesthesia for electroconvulsive therapy to be performed</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebos: Administration of a equidose placebo during the induction and maintenance of anesthesia for electroconvulsive therapy to be performed</description>
          </group>
        </group_list>
        <measure>
          <title>Diastolic Blood Pressure Change</title>
          <description>comparison of diastolic blood pressure change alfentanil vs placebo</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.26" spread="23.3848507043"/>
                    <measurement group_id="O2" value="23.34" spread="24.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Heart Rate</title>
        <description>comparison of heart rate change alfentanil vs placebo</description>
        <time_frame>Baseline and up to 15 seconds</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Alfentanil</title>
            <description>Alfentanil: Administration of alfentanil during the induction and maintenance of anesthesia for electroconvulsive therapy to be performed</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebos: Administration of a equidose placebo during the induction and maintenance of anesthesia for electroconvulsive therapy to be performed</description>
          </group>
        </group_list>
        <measure>
          <title>Heart Rate</title>
          <description>comparison of heart rate change alfentanil vs placebo</description>
          <units>Beats per Minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.00" spread="19.823"/>
                    <measurement group_id="O2" value="28.197674418604" spread="21.486"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Heart Rate</title>
        <description>comparison of heart rate change alfentanil vs placebo</description>
        <time_frame>Baseline and up to 30 seconds</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Alfentanil</title>
            <description>Alfentanil: Administration of alfentanil during the induction and maintenance of anesthesia for electroconvulsive therapy to be performed</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebos: Administration of a equidose placebo during the induction and maintenance of anesthesia for electroconvulsive therapy to be performed</description>
          </group>
        </group_list>
        <measure>
          <title>Heart Rate</title>
          <description>comparison of heart rate change alfentanil vs placebo</description>
          <units>Beats per Minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.48" spread="25.46"/>
                    <measurement group_id="O2" value="36.93" spread="25.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Heart Rate</title>
        <description>comparison of heart rate change alfentanil vs placebo</description>
        <time_frame>90 minutes</time_frame>
        <population>Patients had already been discharged from the Post Anesthesia Care Unit (PACU) at 90 minutes time interval and data were not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Alfentanil</title>
            <description>Alfentanil: Administration of alfentanil during the induction and maintenance of anesthesia for electroconvulsive therapy to be performed</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebos: Administration of a equidose placebo during the induction and maintenance of anesthesia for electroconvulsive therapy to be performed</description>
          </group>
        </group_list>
        <measure>
          <title>Heart Rate</title>
          <description>comparison of heart rate change alfentanil vs placebo</description>
          <population>Patients had already been discharged from the Post Anesthesia Care Unit (PACU) at 90 minutes time interval and data were not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Heart Rate</title>
        <description>comparison of heart rate change alfentanil vs placebo</description>
        <time_frame>Baseline and up to 90 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Alfentanil</title>
            <description>Alfentanil: Administration of alfentanil during the induction and maintenance of anesthesia for electroconvulsive therapy to be performed</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebos: Administration of a equidose placebo during the induction and maintenance of anesthesia for electroconvulsive therapy to be performed</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Heart Rate</title>
          <description>comparison of heart rate change alfentanil vs placebo</description>
          <units>Beats per Minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.33" spread="24.274"/>
                    <measurement group_id="O2" value="49.66" spread="26.629"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Minimum Heart Rate</title>
        <description>comparison of heart rate change alfentanil vs placebo</description>
        <time_frame>Baseline and up to 90 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Alfentanil</title>
            <description>Alfentanil: Administration of alfentanil during the induction and maintenance of anesthesia for electroconvulsive therapy to be performed</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebos: Administration of a equidose placebo during the induction and maintenance of anesthesia for electroconvulsive therapy to be performed</description>
          </group>
        </group_list>
        <measure>
          <title>Minimum Heart Rate</title>
          <description>comparison of heart rate change alfentanil vs placebo</description>
          <units>Beats per Minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.74" spread="14.674"/>
                    <measurement group_id="O2" value="7.08" spread="19.221"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Doses of Antihypertensive Medication</title>
        <description>comparison of amounts of medications needed to treat blood pressure between the 2 groups</description>
        <time_frame>90 minutes</time_frame>
        <population>Patients had already been discharged from the PACU at 90 minutes time interval and data were not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Alfentanil</title>
            <description>Alfentanil: Administration of alfentanil during the induction and maintenance of anesthesia for electroconvulsive therapy to be performed</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebos: Administration of a equidose placebo during the induction and maintenance of anesthesia for electroconvulsive therapy to be performed</description>
          </group>
        </group_list>
        <measure>
          <title>Doses of Antihypertensive Medication</title>
          <description>comparison of amounts of medications needed to treat blood pressure between the 2 groups</description>
          <population>Patients had already been discharged from the PACU at 90 minutes time interval and data were not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0.0"/>
                <count group_id="O2" value="0.0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Return of Spontaneous Ventilation</title>
        <description>time to return to breathing without assistance</description>
        <time_frame>up to 90 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Alfentanil</title>
            <description>Alfentanil: Administration of alfentanil during the induction and maintenance of anesthesia for electroconvulsive therapy to be performed</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebos: Administration of a equidose placebo during the induction and maintenance of anesthesia for electroconvulsive therapy to be performed</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Return of Spontaneous Ventilation</title>
          <description>time to return to breathing without assistance</description>
          <units>Minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.17" spread="2.483"/>
                    <measurement group_id="O2" value="7.25" spread="1.869"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Time Subject Spent In-Room</title>
        <description>comparison of amounts time spent in-room between the 2 groups</description>
        <time_frame>up to 90 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Alfentanil</title>
            <description>Alfentanil: Administration of alfentanil during the induction and maintenance of anesthesia for electroconvulsive therapy to be performed</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebos: Administration of a equidose placebo during the induction and maintenance of anesthesia for electroconvulsive therapy to be performed</description>
          </group>
        </group_list>
        <measure>
          <title>Total Time Subject Spent In-Room</title>
          <description>comparison of amounts time spent in-room between the 2 groups</description>
          <units>Minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.51" spread="4.640"/>
                    <measurement group_id="O2" value="16.43" spread="3.940"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severity of Headache in the Post Anesthesia Care Unit</title>
        <description>comparison between alfentanil vs placebo - Subject questionnaire with scale: 0 -10 - with 10 being the worst</description>
        <time_frame>up to 90 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Alfentanil</title>
            <description>Alfentanil: Administration of alfentanil during the induction and maintenance of anesthesia for electroconvulsive therapy to be performed</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebos: Administration of a equidose placebo during the induction and maintenance of anesthesia for electroconvulsive therapy to be performed</description>
          </group>
        </group_list>
        <measure>
          <title>Severity of Headache in the Post Anesthesia Care Unit</title>
          <description>comparison between alfentanil vs placebo - Subject questionnaire with scale: 0 -10 - with 10 being the worst</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" spread="2.887"/>
                    <measurement group_id="O2" value="2.467" spread="3.038"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Satisfaction With the Anesthetic Post-procedure</title>
        <description>comparison between alfentanil vs placebo - Subject questionnaire with scale: 0-10 - with 10 being the worst</description>
        <time_frame>up to 90 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Alfentanil</title>
            <description>Alfentanil: Administration of alfentanil during the induction and maintenance of anesthesia for electroconvulsive therapy to be performed</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebos: Administration of a equidose placebo during the induction and maintenance of anesthesia for electroconvulsive therapy to be performed</description>
          </group>
        </group_list>
        <measure>
          <title>Satisfaction With the Anesthetic Post-procedure</title>
          <description>comparison between alfentanil vs placebo - Subject questionnaire with scale: 0-10 - with 10 being the worst</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" spread="2.449"/>
                    <measurement group_id="O2" value="8.033" spread="2.505"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 hours</time_frame>
      <desc>Death by suicide the day after one of their electroconvulsive therapy (ECT) procedures was completed - at which time they received Alfentanil during that ECT</desc>
      <group_list>
        <group group_id="E1">
          <title>Alfentanil</title>
          <description>Alfentanil: Administration of alfentanil during the induction and maintenance of anesthesia for electroconvulsive therapy to be performed</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebos: Administration of a equidose placebo during the induction and maintenance of anesthesia for electroconvulsive therapy to be performed</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Suicide</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Suicide</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>T. Quinn McCutchen, MD</name_or_title>
      <organization>Wake Forest Health Science</organization>
      <phone>336.716.4498</phone>
      <email>tmccutch@wakehealth.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

